Abstract
Purpose
The fragile histidine triad (FHIT) gene has recently been proposed as being a tumor suppressor gene. FHIT gene deletions or aberrant transcripts have been identified in a variety of human malignancies, including gastric carcinomas, suggesting that FHIT may play a key role in tumor development. However, the clinical impact of FHIT mutations in gastric carcinogenesis is still debated. Our purpose was to investigate whether FHIT expression in human primary gastric carcinoma is associated with the histological type, grade or stage of the tumor.
Methods
We analyzed a well-characterized set of 137 primary gastric cancers. FHIT protein expression was evaluated in gastric mucosal samples, both from the tumor and tumor-free areas by immunohistochemistry. Furthermore, in a subgroup of 30 patients, FHIT mRNA expression was assessed by nested RT-PCR.
Results
Absent or reduced expression of FHIT protein correlated significantly with diffuse type (P<0.0001), poor differentiation (P<0.0001), and advanced stage (P<0.0001) of gastric cancer. In contrast, FHIT protein was strongly expressed and uniformly distributed in tumor-free areas. The FHIT mRNA expression was absent or altered in diffuse and poorly differentiated carcinomas.
Conclusion
These results show that the expression of FHIT in gastric carcinoma is related to the type, grade, and stage of the tumor. We suggest that FHIT expression may be considered a potential prognostic factor in gastric cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baffa R, Veronese ML, Santoro R, Mandes B, Palazzo JP, Rugge M, Santoro E, Croce CM, Huebner K (1998) Loss of FHIT expression in gastric carcinoma. Cancer Res 58:4708–4714
Capuzzi D, Santoro E, Hauck WW, Kovatich AJ, Rosato FE, Baffa R, Huebner K, McCue PA (2000) FHIT expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer 88:24–34
Correa P (1995) Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 19:37–43
Correa P, Shiao YH (1994) Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 54:1941–1943
Chang YT, Wu MS, Chang CJ, Huang PH, Hsu SM, Lin JT (2002) Preferential loss of FHIT expression in signet-ring cell and Krukenberg subtypes of gastric cancer. Lab Invest 82:1201–1208
Ebert M, Yokoyama M, Kobrin MS, Friess H, Lopez ME, Büchler MW, Korc M (1994) Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res 54:3959–3962
Fong LYY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, Mancini R, Siprashvili Z, Ottey M, Martin SE, Druck T, McCue PA, Croce CM, Heubner K (2000) Muir-Torre-like syndrome in FHIT-deficient mice. Proc Natl Acad Sci USA 97:4742–4747
Fuchs CS, Mayer RJ (1995) Gastric carcinoma. N Engl J Med 333:32–41
Gemma A, Hagiwara K, Ke Y, Burke LM, Khan MA, Nagashima M, Bennett WP, Harris CC (1997) FHIT mutations in human primary gastric cancer. Cancer Res 57:1435–1437
Hansson LE, Sparen P, Nyren O (1999) Survival in stomach cancer is improving: results of a nation-wide population-based Swedish study. Ann Surg 230:162–169
Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA (1999) Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 59:3333–3339
Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Path Microb Scand 64:31–49
Lee SH, Kim WH, Kim HK, Woo KM, Nam HS, Kim HS, Kim JG, Cho MH (2001a) Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas. Biochem Biophys Res Commun 284:850–855
Lee SH, Kim WH, Park HK, Koh JW, Cho MH, Baek MJ, Lee MS (2001b) Characterization of aberrant FHIT transcripts in gastric adenocarcinomas. Exp Mol Med 33:124–130
Marchetti A, Pellegrini S, Bertacca G, Buttitta F, Gaeta P, Carnicelli V, Nardini V, Griseri P, Chella A, Angeletti CA, Bevilacqua G (1998) FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations. J Pathol 184:240–246
Ming S (1998) Cellular and molecular pathology of gastric carcinoma and precursor lesions: a critical review. Gastric Cancer 1:31–50
Noguchi T, Muller W, Wirtz HC, Willers R, Gabbert HE (1999) FHIT gene in gastric cancer: association with tumor progression and prognosis. J Pathol 188:378–81
Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587–597
Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality of 25 cancers in 1990. Int J Cancer 83:18–29
Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, Colombo MP,Gramegna M, Croce CM, Pierotti MA, Sozzi G (1999) The tumor-suppresser gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 96:8489–8492
Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM, Heubner K (1997) Replacement of FHIT in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 94:13771–13776
Sozzi G, Tornielli S, Tagliabue E, Sard L, Pezzella F, Pastorino U, Minoletti F, Pilotti S, Ratcliffe C, Veronese ML, Goldstraw P, Huebner K, Croce CM, Pienotti MA (1997) Absence of FHIT protein in primary lung tumours and cell lines with FHIT gene abnormalities. Cancer Res 57:5207–5212
Stemmermann G, Heffelfinger SC, Noffsinger A, Hui YZ, Miller MA, Fenoglio-Preiser CM (1994) The molecular biology of oesophageal and gastric cancer and their precursors: oncogenes, tumor suppresser genes, and growth factors. Hum Pathol 25:968–981
Tahara E (1993) Molecular mechanisms of stomach carcinogenesis. J Cancer Res Clin Oncol 119:265–272
Tahara E (1995) Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis. Cancer 75:1410–1417
Tamura G, Sakata K, Nishizuka S, Maesawa C, Suzuki Y, Iwaya T, Terashima M, Saito K, Satodate R (1997) Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines. Genes Chromosomes Cancer 20:98–102
Tanimoto K, Hayashi S, Tsuchiya E, Tokuchi Y, Kobayashi Y, Yoshiga K, Okui T, Kobayashi M, Ichikawa T (2000) Abnormalities of the FHIT gene in human oral carcinogenesis. Br J Cancer 82:838–842
Thompson GB, van Heerden JA, Sarr MG (1993) Adenocarcinoma of the stomach: are we making progress? Lancet 342:713–718
Yang Q, Nakamura M, Nakamura Y, Yosimura G, Suzuma T, Umemura T, Shimizu Y, Mori I, Sakurai T, Kakudo K (2002) Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Clin Cancer Res 8:2890–2893
Wistuba II, Ashfaq R, Maitra A, Alvarez H, Riquelme E, Gazdar AF (2002) Fragile histidine triad gene abnormalities in the pathogenesis of gall bladder carcinoma. Am J Pathol 160:2073–2079
Wright PA, Williams GT (1993) Molecular biology and gastric carcinoma. Gut 34:145–147
Acknowledgements
This study was supported by grants awarded from the DAAD and DFG. M. Ebert is supported by the Heisenberg-Programme (Eb 187/5–1) of the DFG.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rocco, A., Schandl, L., Chen, J. et al. Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer. J Cancer Res Clin Oncol 129, 84–88 (2003). https://doi.org/10.1007/s00432-002-0409-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-002-0409-3